Glaucoma – Global Drug Forecast and Market Analysis to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Glaucoma Market Report Overview
The Glaucoma market size across the 7MM was valued at $2.8 billion in 2020 and will achieve a CAGR of more than 1% during 2020-2030. A projected increase in the prevalence of glaucoma throughout the 7MM resulting from an ageing population will drive market growth during the forecast period.
Glaucoma Market Outlook, 2020-2030 ($ Billion)
Buy the Full Report to Gain More Information on the Glaucoma Market Forecast
The Glaucoma market research covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and provides a forecast model for the Glaucoma market through 2030.
Market Size (2020) | $2.8 billion |
CAGR (2020-2030) | >1% |
Key Class of Drugs | · Prostaglandin Analogues
· Fixed-Dose Combination Therapies · Beta Blockers · Carbonic Anhydrase Inhibitors · Alpha-Adrenergic Agonist |
Leading Players | · Pfizer
· Nicox · Sylentis SAU, D.c · Sylentis SAU · pH Pharma Co Ltd |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Glaucoma Market Insights
Poor adherence to therapy will continue to stymie the sales of topical glaucoma therapies throughout the forecast period. The projected launch of sustained-release (SR) implants, which are expected to help meet unmet needs in this market by improving patient compliance will propel the market growth in the coming years.
Glaucoma - Treatment Insights
- In recent years, many pharmaceutical companies have focused on developing products outside of the conventional classes for glaucoma treatment to provide a new MOA to reduce IOP that can be utilized adjunctively to existing
- Sylentis SAU’s bamosiran and D. Western Therapeutics’ h-1337 are both set to launch towards the beginning of the forecast period and will offer drugs with a novel MOA for glaucoma treatment that will provide ophthalmologists further options to lower IOP in patients with intractable IOP.
- Allergan’s Durysta (bimatoprost SR) is the first sustained-release implant that has been approved and launched for the treatment of glaucoma within the US. This is anticipated to be well received by ophthalmologists and thereby driving the market growth.
Buy the Full Report for More Glaucoma Treatment Insights
Glaucoma Market Segmentation by Class of Drugs
In 2020, the leading drug class in the US glaucoma market was Prostaglandin Analogues.
The key classes of drugs in the US glaucoma market are Prostaglandin Analogues, Fixed-Dose Combination Therapies, Beta Blockers, Carbonic Anhydrase Inhibitors, and Alpha-Adrenergic Agonist. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta-blockers (BBs), α-adrenergic receptor agonists (AAs), carbonic anhydrase inhibitors (CAIs), and Rho kinase inhibitors (RKIs.
Victoza.
Glaucoma Market Analysis by Class of Drugs, 2020 (%)
Buy the Full Report for More Drugs Insights into the US Glaucoma Market
Glaucoma Market - Competitive Landscape
A few of the leading players in the Glaucoma market are:
- Pfizer
- Nicox
- Sylentis SAU, D.c
- Sylentis SAU
- pH Pharma Co Ltd.
The Glaucoma market is very mature and dominated by generic versions of therapies originally developed by companies like Alcon and Pfizer. Despite this, there are still a few companies that dominate within this disease space, as well as others that currently show a modest line of pipeline agents in development.
Glaucoma Market Analysis by Companies
Buy the Full Report for More Glaucoma Company Insights
Scope
This report provides:
- Overview of Glaucoma, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Glaucoma market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Glaucoma therapeutics market.
- Comprehensive data assessing emerging trends and mechanisms of action under development for Glaucoma treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global Glaucoma therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Glaucoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Glaucoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Bausch & Lamb
Nic0x
Mallinckrodt Plc
Santen
Merck
Bruschettini Srl
Aerie Pharmaceuticals
Otsuka Pharmaceutical
Aton
Thea Pharma
Novatis
Kowa Co Ltd
Sandoz International
OmniVision
Eisai Co Ltd
Concordia International
Teofarma Srl
Sanwa Kagaku Kenkyusho
Ocular Therapeutix Inc
ViSci Ltd
Ono Pharmaceutical
D. Western Therapeutics
Sylentis SAU
pH Pharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What was the Glaucoma market size across the 7MM in 2020?
The Glaucoma market size across the 7MM was valued at $2.8 billion in 2020.
-
What will the Glaucoma market growth rate be during the forecast period?
The Glaucoma market will achieve a CAGR of more than 1% during 2020-2030.
-
Which drug was the highest selling in the Glaucoma market in 2020?
Prostaglandin Analogues was the highest-selling drug in 2020.
-
Who are the leading players in the Glaucoma market?
A few of the leading players in the Glaucoma market are Pfizer, Nicox, Sylentis SAU, D.c, Sylentis SAU, and pH Pharma Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.